May 26, 2016

Celerity Partners Exits SynteractHCR

Gryphon Investors has sold SynteractHCR to Amulet Capital Partners, LP (“Amulet”). Celerity Partners, who sold a majority interest to Gryphon in 2008, has remained active in the project through the sale of the Company as a minority shareholder with a seat on the Board.

SynteractHCR is a leading contract research organization (CRO) focused on Phase I‐IV clinical trials for emerging to mid-sized biopharma clients in the U.S., Europe, and Asia. SynteractHCR was founded in 1995 and is headquartered in Carlsbad, California. The company has grown revenues by a factor of five since Celerity made its initial investment and is now a top 20 global full-service CRO.  The company’s operations include over 800 staff members across 21 countries. SynteractHCR has a reputation for clinical excellence in complex trials in a broad range of therapeutic areas, contributing to more than 230 product approvals since its founding. The company has run over 3,500 projects including more than 700,000 patients in 60+ countries.